Table 1.
Author | Study Design | MSC Delivery | Cell Source | MSC Dosage | CP | Participants (n) |
---|---|---|---|---|---|---|
Mendonca et al., 2014 [61] | UC, NonRand | IT | Au, BM | 1 × 107 | None | 12 |
Vaquero et al., 2018 [62] | UC, NonRand | IT | Au, BM | 3 × 108 | 10% DMSO | 11 |
Oh et al., 2016 [63] | UC, NonRand | IT | Au, BM | 4.8 × 107 | None | 16 |
Hur et al., 2016 [15] | UC, NonRand | IT | Au, AT | 9 × 107 | None | 14 |
Vaquero et al., 2017 [64] | UC, NonRand | IT | Au, BM | 1.2 × 108 | NS | 10 |
Cheng et al., 2014 [65] | C, Rand | IT | Allo, UC | 4 × 107 | None | 10 treated 24 control |
Dai et al., 2013 [66] | C, Rand | IT | Au, BM | 8 × 105 (MS) | None | 20 treated 20 control |
Karamouzian et al., 2012 [14] | C, NonRand | LP | Au, BM | 0.7–1.2 × 106 | None | 11 |
Ra et al., 2011 [67] | UC, NonRand | IV | Au, AT | 4 × 108 | None | 8 |
Pal et al., 2009 [68] | UC, NonRand | LP | Au, BM | 1 × 106/kg | NS | 30 |
Vaquero et al., 2016 [69] | UC, NonRand | IT | Au, BM | 1.3–2.6 × 108 | NS | 12 |
El-Kheir et al., 2014 [70] | C, Rand | LP | Au, BM | 2 × 106/kg | None | 50 treated 20 control |
Phedy et al., 2019 [71] | Case study | IT + IV | Au, BM | 69.5 × 106 | NS | 1 |
Bydon et al., 2020 [72] | Case study | LP | Au, AT | 1 × 108 | NS | 1 |
Larocca et al., 2017 [73] | Pilot, UC, NonRand | IT | Au, BM | 2 × 107 | None | 5 |
Chotivichit et al., 2015 [74] | Pilot, UC, NonRand | IT | Au, BM | 3 × 107 | None | 1 |
Hua et al., 2016 [75] | Pilot, UC, NonRand | IT | Au, UC | 4 × 107 | None | 1 |
Jarocha et al., 2015 [76] | Case study | IT + IV | Au, BM | 1.54 × 108 | None | 1 |
Park et al., 2012 [77] | UC, NonRand | LP | Au, BM | 1.48 × 108 | 10% DMSO | 10 |